Efficacy of acetylleucine in vertigo and dizziness: a systematic review of randomised controlled trials

Paul, Vanaja; Blanchard, Clara; Naudet, Florian; Pouchain, Denis; Roussel, H.; Pérault-Pochat, Marie Christine; Jaafari, Nématollah; Boussageon, Rémy

doi:10.1007/s00228-018-02617-6

Cited by 12 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it seems that symptoms progressed regardless of the administration of this drug. This is in line with a recent systematic review of randomised controlled trials that affirms that there is no solid evidence of the efficacy of acetylleucine in vertigo/dizziness [79].…”

Section: Discussionsupporting

confidence: 90%

Vestibular disorders following BNT162b2 mRNA COVID‐19 vaccination: A retrospective case series

Ammar

Beller

Bouccara

et al. 2023

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

BackgroundThere are few publications regarding manifestations of vestibular disorders (VDs) following BNT162b2 mRNA COVID‐19 vaccination.PurposeWe describe cases of VD potentially related to BNT162b2 vaccination and calculate its reporting rate, in order to enlarge knowledge about this adverse effect.MethodsA retrospective analysis of cases of VD following BNT162b2 vaccination reported to the pharmacovigilance centre of Georges‐Pompidou European Hospital (France), in 2021 was performed. In order to identify these cases from the pharmacovigilance database containing all our registered cases, we used the Standardised MedDRA Query (SMQ) ‘vestibular disorders’. Then we analysed cases with vestibular symptoms, based on the association of typical manifestations. The reporting rate was calculated based on the number of VD cases and the number of vaccinated patients.ResultsAmong 6608 cases reported to our centre related to COVID‐19 vaccines during 2021, 34 VDs associated with BNT162b2 administration were included. They were mainly reported in females (79%), 62% occurred after the first dose and 32% were serious. Symptoms had completely resolved in 13 cases (38%). Vertigo was the most common symptom followed by balance disorders. Three patients received second dose without reappearance of VD. The final diagnosis was reported in 10 patients (six cases of vestibular neuritis, two cases of central VD, two cases of benign paroxysmal positional vertigo). The regional reporting rate was 26 [95% CI: 17–34] cases of VD per 1 million persons vaccinated.ConclusionAlthough the relationship between vaccination and VD cannot be established, clinicians should be aware of this rare adverse effect.

show abstract

Section: Discussionsupporting

confidence: 90%

Vestibular disorders following BNT162b2 mRNA COVID‐19 vaccination: A retrospective case series

Ammar

Beller

Bouccara

et al. 2023

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…The comparative study of the antivertigo (AV) effects produced by the administration of apamin or acetyl-DL-leucine (ADLL) in vestibulo-injured rats allows anticipation of the potential of apamin to alleviate the vertigo symptoms compared to the French reference AV compound [35]. Apart from a statistically significant difference in the effect of ADLL vs. control and apamin visible at D3 in the subjective evaluation of vertigo syndrome, the AV effect of apamin is always superior to that of ADLL, regardless of the criteria and time point considered.…”

Section: Superior Av Effect Of Apamin Vs Acetyl-dl-leucinementioning

confidence: 99%

SK Channels Modulation Accelerates Equilibrium Recovery in Unilateral Vestibular Neurectomized Rats

et al. 2021

View full text Add to dashboard Cite

We have previously reported in a feline model of acute peripheral vestibulopathy (APV) that the sudden, unilateral, and irreversible loss of vestibular inputs induces selective overexpression of small conductance calcium-activated potassium (SK) channels in the brain stem vestibular nuclei. Pharmacological blockade of these ion channels by the selective antagonist apamin significantly alleviated the evoked vestibular syndrome and accelerated vestibular compensation. In this follow-up study, we aimed at testing, using a behavioral approach, whether the antivertigo (AV) effect resulting from the antagonization of SK channels was species-dependent or whether it could be reproduced in a rodent APV model, whether other SK channel antagonists reproduced similar functional effects on the vestibular syndrome expression, and whether administration of SK agonist could also alter the vestibular syndrome. We also compared the AV effects of apamin and acetyl-DL-leucine, a reference AV compound used in human clinic. We demonstrate that the AV effect of apamin is also found in a rodent model of APV. Other SK antagonists also produce a trend of AV effect when administrated during the acute phase of the vertigo syndrome. Conversely, the vertigo syndrome is worsened upon administration of SK channel agonist. It is noteworthy that the AV effect of apamin is superior to that of acetyl-DL-leucine. Taken together, these data reinforce SK channels as a pharmacological target for modulating the manifestation of the vertigo syndrome during APV.

show abstract

“…This characteristic phenotype is also observed during unilateral peripheral vestibular involvement due to vestibular neuritis, Meniere’s disease or a labyrinthine fistula [ 2 ]. Pharmacological approaches to attenuate the acute vertigo episodes remain poorly effective due to the lack of specific treatments available for these pathologies [ 3 , 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of Fluoxetine and Acacetin on Central Vestibular Compensation in an Animal Model of Unilateral Peripheral Vestibulopathy

Hatat¹,

Boularand²,

Bringuier³

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Damage to the peripheral vestibular system is known to generate a syndrome characterized by postural, locomotor, oculomotor, perceptual and cognitive deficits. Current pharmacological therapeutic solutions for these pathologies lack specificity and efficacy. Recently, we demonstrated that apamin, a specific SK channel blocker, significantly reduced posturo-locomotor and oculomotor deficits in the cat and the rat. The aim of the present study was to test the antivertigo potential of compounds belonging to the SK antagonists family, such as Acacetin and Fluoxetine. Young rats were subjected to unilateral ototoxic lesions of the vestibular organ using transtympanic administration of arsanilic acid (TTA) to evoke unilateral vestibular loss (UVL). Vestibular syndrome was monitored using behavioural evaluation allowing appreciation of the evolution of static and dynamic posturo-locomotor deficits. A significant effect of the TTA insult was only found on the distance moved, the mean body velocity and the not moving time. From day 2 to week 2 after TTA, the distance moved and the mean body velocity were significantly decreased, while the not moving time was significantly increased. Acacetin does not evoke any significant change in the vestibular posturo-locomotor parameters’ kinetics. Administration of Fluoxetine two weeks before TTA and over three weeks after TTA (preventive group) does not evoke any significant change in the vestibular posturo-locomotor parameters’ kinetics. Administration of Fluoxetine from three weeks after TTA significantly delayed the functional recovery. This study demonstrates that Acacetin or Fluoxetine in TTA vestibulo-injured rats does not bring any significant benefit on the posture and locomotor balance deficits.

show abstract

Efficacy of acetylleucine in vertigo and dizziness: a systematic review of randomised controlled trials

Cited by 12 publications

References 28 publications

Vestibular disorders following BNT162b2 mRNA COVID‐19 vaccination: A retrospective case series

Vestibular disorders following BNT162b2 mRNA COVID‐19 vaccination: A retrospective case series

SK Channels Modulation Accelerates Equilibrium Recovery in Unilateral Vestibular Neurectomized Rats

Effect of Fluoxetine and Acacetin on Central Vestibular Compensation in an Animal Model of Unilateral Peripheral Vestibulopathy

Contact Info

Product

Resources

About